Extended Shelf Life Approved for Taxus(R) Stent System
May 23, 2005 - 7:50:00 PM
"The extended shelf life of TAXUS offers an additional benefit to physicians and other healthcare professionals making purchasing decisions for drug-eluting stents."
By Boston Scientific Corporation, [RxPG] Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS(R)Express2(TM) paclitaxel-eluting coronary stent system in the United States to twelve months from the current shelf life of nine months.
The decision was based on data submitted by Boston Scientific to the FDA that demonstrated the performance of the TAXUS system -- in particular the drug content, drug
degradation profile and drug-release mechanism -- was maintained within FDA-approved specifications at twelve months. The new TAXUS U.S. shelf life is longer than any competing product.
The extended expiration date applies to all sizes of the TAXUS system for sale in the United States. The Company said it would immediately begin updating labels to reflect the twelve-month expiration date. The shelf life for the TAXUS system outside the United States remains unchanged at 18 months.
"The extended shelf life of TAXUS offers an additional benefit to physicians and other healthcare professionals making purchasing decisions for drug-eluting stents," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "The extended shelf life may facilitate inventory management for hospitals concerned with issues of stock rotation or product expiration."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:
http://www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired
companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol
508-650-8569
Investor Relations
Boston Scientific Corporation
Paul Donovan
508-650-8541 (Office)
508-667-5165 (Mobile)
Media Relations
Boston Scientific Corporation
Feedback
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
